China urges firms to make generic versions of 34 drugs
June 25, 2019Research and Development China, NHC, generic drugs, generics, patents, pharma
China’s National Health Commission (NHC) has urged generic drugmakers to pick up the production of 34 drugs that are not …
FREE WEBINAR: Virtually engaged or engaged virtually?
June 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, Within3, pharma
In just over a week, on Wednesday 4 July, Pharmafocus will be collaborating with Healthcare Engagement Solutions firm Within3 to …
FDA knocks back Glenmark’s allergic rhinitis therapy Ryaltris
June 25, 2019Manufacturing and Production, Sales and Marketing FDA, Glenmark, Ryaltris, US, allergy, pharma
Stocks in Indian pharmaceutical firm Glenmark were sent plummeting to a six-year low after it was confirmed that the FDA …
Minerva’s insomnia treatment beats Ambien in Phase 2b trial
June 25, 2019Manufacturing and Production MDD, Minerva Neurosciences, Placebo, ambien, insomnia, pharma, zolpidem
Massachusetts-based firm Minerva Neurosciences has announced that its sleeping pill seltorexant beat both Sanofi’s Ambien (zolpidem) and placebo in treating …
Kamala Harris hopes to make insurance companies cover PrEP at no out-of-pocket cost to patients
June 25, 2019Manufacturing and Production, Sales and Marketing
Democratic presidential candidate Kamala Harris has introduced a bill which would require all private and public insurance plans to cover …
Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger
June 24, 2019Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …
The Brexit ‘cliff edge’: How life sciences can survive
June 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, brexit, pharma
Characterised by a persistent lack of clarity and a political climate that has everyone guessing from week to week, Brexit …
Pfizer’s Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations
June 24, 2019Sales and Marketing Pfizer, breast cancer, oncology, pharma
Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker …
Glenmark signs deal with Novartis over distribution in Brazil
June 24, 2019Sales and Marketing Brazil, Glenmark, Latin America, Novartis, distribution, pharma
Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil. …
FDA expands Vertex’s cystic fibrosis drug Symdeko in paediatric patients
June 24, 2019Sales and Marketing FDA, Symdeko, Vertex, cystic fibrosis, pharma
Vertex has announced that the FDA has chosen to expand the existing authorisation on its cystic fibrosis (CF) therapy Symdeko …
FDA approve libido enhancing drug for women with low sexual desire
June 24, 2019Sales and Marketing FDA, HSDD, health, pharma, viagra, vyleesi
The FDA has approved a new drug for women with low libido.The FDA has approved AMAG Pharmaceuticals’ bremelanotide – sold …
One third of Brits stockpile drugs
June 24, 2019Sales and Marketing UK, medicine, pharma, pharmaceuticals, stockpiling
A third (33%) of brits stockpile medicines, according to new research from Co-op Health. One in three British people never …
Top Ten most popular articles on Pharmafile.com this week
June 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, MSD, Parkinson's, blockchain, brexit, top ten
It’s Friday, and time for another run-down of the week’s most popular articles.
European approval for Novo’s Esperoct in haemophilia A
June 21, 2019Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma
The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for …
Sanofi to axe 466 R&D positions in Germany and France
June 21, 2019Medical Communications, Research and Development, Sales and Marketing Sanofi, pharma
Sanofi has announced that plans to reorganise its research and development operations will result in the losses of 466 jobs …
GSK offers concessions ahead of planned venture with Pfizer
June 21, 2019Medical Communications, Sales and Marketing GSK, Pfizer, pharma
The European Commission has said that GlaxoSmithKline has offered concessions to address concerns relating to the British multinational’s planned joint …
Alimera Sciences secures NICE recommendation for uveitis eye implant
June 21, 2019Medical Communications, Sales and Marketing Alimera Sciences, NICE, UK, pharma, uveitis
Britain’s cost effectiveness body NICE has recommended the use of the fluocinolone acetonide implant, a new treatment option for patients …
Catalent to purchase Italy manufacturing facility from BMS
June 20, 2019Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, Cataletnt, pharma
Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in …
Scientists at King’s College London identify early signs of Parkinson’s disease
June 20, 2019Research and Development King's College London, Kings College London, Parkinson's disease, pharma, serotonin
Scientists at King’s College London say they have identified the earliest signs of Parkinson’s disease in the brain – 15 …
Gilead signs deal with Nurix Therapeutics worth more than $2.3 billion
June 20, 2019Business Services, Research and Development Gilead, Nurix Therapeutics, pharma, protiens
Gilead has signed a deal with San Francisco biotech Nurix Therapeutics – a company focused on developing drugs that control …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
